AKRO Live signals | Maximize Profits with Getagraph.com

BUY 102295 min ago

@ $22.13

Issued: 14 Feb 2024 @ 14:43

Return: -14.46%

Previous signal: Feb 13 - 15:49

Previous signal: Sell

Return: 7.64 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health...

Stats
Today's Volume	827 380
Average Volume	1.40M
Market Cap	1.31B
EPS	$0 ( 2024-03-15 )
Next earnings date	( $-0.860 ) 2024-05-12
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.55
ATR14	$0.0280 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Young Jonathan	Sell	4 600	Common Stock
2024-04-01	Young Jonathan	Sell	400	Common Stoek
2024-03-13	Yale Catriona	Sell	723	Common Stock
2024-03-13	White William Richard	Sell	724	Common Stock
2024-03-13	Cheng Andrew	Sell	1 969	Common Stock

INSIDER POWER
52.13
Last 100 transactions
Buy: 2 061 541 \| Sell: 638 251

Volume Correlation

Long: -0.39 (neutral)

Short: -0.91 (very strong negative)

Signal:(37.36) Neutral

Akero Therapeutics Inc Correlation

10 Most Positive Correlations
AZYO	0.936
GNSS	0.933
VRAR	0.929
UBOH	0.929
NVCT	0.922
CULL	0.919
VERA	0.919
JRJC	0.918
EDSA	0.917
BRQS	0.91

10 Most Negative Correlations
RXDX	-0.979
FLMN	-0.968
ZYNE	-0.962
RESN	-0.962
ZGNX	-0.959
CYT	-0.958
ADMS	-0.946
RETA	-0.946
ORTX	-0.938
XLRN	-0.931

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Akero Therapeutics Inc Correlation - Currency/Commodity

-0.48
( neutral )

-0.06
( neutral )

0.00
( neutral )

-0.44
( neutral )

0.68
( moderate )

-0.23
( neutral )

Akero Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-29 000.00 (0.00 %)
EPS:	$-2.89

Q4	2023
Revenue:	$284 000
Gross Profit:	$282 000 (99.30 %)
EPS:	$-0.990

Q3	2023
Revenue:	$0
Gross Profit:	$-5 000.00 (0.00 %)
EPS:	$-0.710

Q2	2023
Revenue:	$0
Gross Profit:	$-69 000.00 (0.00 %)
EPS:	$-0.600

Financial Reports:

No articles found.

Akero Therapeutics Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.